JP2017512753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512753A5 JP2017512753A5 JP2016552329A JP2016552329A JP2017512753A5 JP 2017512753 A5 JP2017512753 A5 JP 2017512753A5 JP 2016552329 A JP2016552329 A JP 2016552329A JP 2016552329 A JP2016552329 A JP 2016552329A JP 2017512753 A5 JP2017512753 A5 JP 2017512753A5
- Authority
- JP
- Japan
- Prior art keywords
- paricalcitol
- dose
- epoetin
- week
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims 15
- 229960000987 paricalcitol Drugs 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000007502 anemia Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108010002601 epoetin beta Proteins 0.000 claims 3
- 229960004579 epoetin beta Drugs 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims 2
- 229960003388 epoetin alfa Drugs 0.000 claims 2
- 108010067416 epoetin delta Proteins 0.000 claims 2
- 229950002109 epoetin delta Drugs 0.000 claims 2
- 108010030868 epoetin zeta Proteins 0.000 claims 2
- 229950005185 epoetin zeta Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
| ESP201430177 | 2014-02-11 | ||
| PCT/EP2015/050817 WO2015121022A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512753A JP2017512753A (ja) | 2017-05-25 |
| JP2017512753A5 true JP2017512753A5 (OSRAM) | 2018-02-22 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552329A Pending JP2017512753A (ja) | 2014-02-11 | 2015-01-16 | 炎症性貧血の処置におけるパリカルシトールの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (OSRAM) |
| EP (1) | EP3104872B1 (OSRAM) |
| JP (1) | JP2017512753A (OSRAM) |
| KR (1) | KR20160113664A (OSRAM) |
| CN (1) | CN106061498B (OSRAM) |
| AR (1) | AR099330A1 (OSRAM) |
| AU (1) | AU2015217956B2 (OSRAM) |
| CA (1) | CA2938057A1 (OSRAM) |
| DK (1) | DK3104872T3 (OSRAM) |
| ES (2) | ES2472040B1 (OSRAM) |
| IL (1) | IL247207B (OSRAM) |
| MX (1) | MX365096B (OSRAM) |
| PT (1) | PT3104872T (OSRAM) |
| RU (1) | RU2016131412A (OSRAM) |
| UY (1) | UY35989A (OSRAM) |
| WO (1) | WO2015121022A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022030665A1 (ko) * | 2020-08-05 | 2022-02-10 | 경상대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| GB2413328A (en) * | 2004-04-23 | 2005-10-26 | Cambridge Antibody Tech | Erythropoietin protein variants |
| CA2674368A1 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Ceased
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en not_active Ceased
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018234568A3 (en) | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| JP2015057451A5 (OSRAM) | ||
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| JP2012193216A5 (OSRAM) | ||
| EP3731847A4 (en) | PULSED ADMINISTRATION OF INHALED NITROGEN OXIDE FOR THE TREATMENT OF PULMONIC HYPERTENSION | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| MX2018006903A (es) | Composicion farmaceutica. | |
| JP2015537009A5 (OSRAM) | ||
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| IL280083A (en) | A pharmaceutical dosage form that can be administered orally and with a modified release | |
| PL3888647T3 (pl) | Kompozycja farmaceutyczna zawierająca podwójny inhibitor ezh1/2 do stosowania jako lek złożony | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP2017512753A5 (OSRAM) | ||
| HK1218862A1 (zh) | 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法 | |
| EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением | |
| JP2017517574A5 (OSRAM) | ||
| WO2016163818A3 (ko) | 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물 | |
| RU2016131412A (ru) | Применение парикальцитола для лечения воспалительной анемии | |
| SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها |